{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:04Z","timestamp":1783161424805,"version":"3.54.6"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.clinthera.2012.01.009","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T19:38:34Z","timestamp":1327952314000},"page":"272-281","source":"Crossref","is-referenced-by-count":14,"title":["Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Brian L.","family":"Abbott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.01.009_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib2","doi-asserted-by":"crossref","first-page":"A1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib3","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2012.01.009_bib4","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic myeloid leukemia: mechanisms of resistance and treatment","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clinthera.2012.01.009_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2012.01.009_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2012.01.009_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2012.01.009_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part 1: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib11","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib12","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib13","series-title":"Sprycel (dasatinib) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.01.009_bib14","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.01.009_bib15","series-title":"Tasigna (nilotinib) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.01.009_bib16","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.01.009_bib17","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2012.01.009_bib18","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","article-title":"Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells","volume":"65","author":"Nam","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.01.009_bib19","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1 positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib20","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib21","doi-asserted-by":"crossref","first-page":"A7009","DOI":"10.1200\/jco.2008.26.15_suppl.7009","article-title":"Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)","volume":"26","author":"Mauro","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib22","first-page":"A0880","article-title":"Dasatinib efficacy in patients with imatinib-resistant\/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program","volume":"93","author":"Saglio","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2012.01.009_bib23","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib24","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib25","doi-asserted-by":"crossref","first-page":"A7007","DOI":"10.1200\/jco.2009.27.15_suppl.7007","article-title":"Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS)","volume":"27","author":"Stone","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2012.01.009_bib27","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib28","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib29","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib30","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib31","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib32","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib33","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2012.01.009_bib34","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.12033","article-title":"Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase","volume":"92","author":"Palandri","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2012.01.009_bib35","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.11381","article-title":"Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2012.01.009_bib36","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","article-title":"Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa","volume":"17","author":"Marin","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2012.01.009_bib37","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib38","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.01.009_bib39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1 treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib40","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2012.01.009_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2012.01.009_bib42","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon \u03b1","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2012.01.009_bib43","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2012.01.009_bib44","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib45","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib46","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.V112.11.2113.2113","article-title":"Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib47","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase II study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.01.009_bib48","first-page":"391","article-title":"Dasatinib efficacy in patients with imatinib-resistant\/-intolerant chronic myeloid leukemia in accelerated phase: 24-month data from START-A","volume":"93","author":"Rea","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2012.01.009_bib49","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2012.01.009_bib50","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V112.11.450.450","article-title":"Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]","volume":"112","author":"Baccarani","year":"2008","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib52","doi-asserted-by":"crossref","first-page":"A4265","DOI":"10.1182\/blood.V112.11.4265.4265","article-title":"The vast majority of CML-CP patients treated with dasatinib (70 mg BID) who progress after long-term follow-up (24 mo) remain in chronic-phase","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2012.01.009_bib53","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"226","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.009_bib54","doi-asserted-by":"crossref","first-page":"A6512","DOI":"10.1200\/jco.2011.29.15_suppl.6512","article-title":"Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib","volume":"29","author":"Shah","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib55","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/cncr.24325","article-title":"Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2012.01.009_bib56","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2009.156","article-title":"Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2012.01.009_bib57","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.01.009_bib58","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.009_bib59","article-title":"Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","author":"Kantarjian","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T08:45:49Z","timestamp":1640594749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0149291812000100"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}